BOURLA ALBERT 4

What Happened Albert Bourla, Chairman & CEO of Pfizer Inc., was granted 911 units tied to Pfizer common stock (phantom shares) on April 14, 2026. The units were reported at $27.11 per share, a total reported value of $24,697. This was an award (derivative grant) under Pfizer's compensation/benefits plan, not an open-market purchase or sale.

Key Details

• Transaction date and price: 2026-04-14 — 911 units at $27.11 per unit (total $24,697).
• Transaction type: Award/Grant of derivative units (code A on Form 4).
• Shares owned after transaction: Not specified in the provided filing details.
• Footnotes: F1 — each unit represents one phantom share of common stock. F2 — units were granted under the Pfizer Nonfunded Deferred Compensation and Supplemental Savings Plan; they are settled in cash after separation from service and may be transferred into an alternative investment account at any time.
• Filing timeliness: Report filed 2026-04-16 for the 2026-04-14 transaction — appears to be timely.

Context These units are phantom/deferred-compensation awards that are settled in cash rather than immediate stock transfers, so they do not directly increase the insider's voting stock. Such awards are common in executive compensation and are not the same as an outright stock purchase (which some investors view as a stronger bullish signal). The reported value here is modest for an executive grant; the filing provides no indication of any sale or immediate conversion of shares.